Holen Sie sich die Stockscreener-App
0.7737
3.92%
-0.0316
Schlusskurs vom Vortag:
$0.8053
Offen:
$0.7775
24-Stunden-Volumen:
1.07M
Relative Volume:
0.75
Marktkapitalisierung:
$45.49M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-123.46M
KGV:
-0.2987
EPS:
-2.59
Netto-Cashflow:
$-104.11M
1W Leistung:
-6.35%
1M Leistung:
+21.14%
6M Leistung:
+59.43%
1J Leistung:
-51.94%
1-Tages-Spanne:
$0.7501
$0.804
1-Wochen-Bereich:
$0.7501
$0.8984
52-Wochen-Spanne:
$0.2601
$1.62
Bioatla Inc Stock (BCAB) Company Profile
Firmenname
Bioatla Inc
Sektor
Branche
Telefon
858-558-0708
Adresse
11085 TORREYANA ROAD, SAN DIEGO
Vergleichen Sie BCAB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BCAB
Bioatla Inc
|
0.7737 | 47.35M | 0 | -123.46M | -104.11M | -2.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.64 | 110.88B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
726.21 | 72.79B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
890.11 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.46 | 54.85B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
189.85 | 41.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Bioatla Inc Stock (BCAB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-13 | Herabstufung | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-11-13 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-09-15 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-05-05 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-03-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2021-06-28 | Eingeleitet | ROTH Capital | Buy |
| 2021-05-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-01-11 | Eingeleitet | BTIG Research | Buy |
| 2021-01-11 | Eingeleitet | Credit Suisse | Outperform |
| 2021-01-11 | Eingeleitet | JP Morgan | Overweight |
| 2021-01-11 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Bioatla Inc Aktie (BCAB) Neueste Nachrichten
Taking on analysts’ expectations and winning: BioAtla Inc (BCAB) - Setenews
Is BioAtla Inc. stock positioned well for digital economyTrade Risk Report & Safe Entry Trade Signal Reports - Newser
Will BioAtla Inc. stock continue dividend increasesJuly 2025 Levels & Stepwise Entry and Exit Trade Signals - Newser
Why BioAtla Inc. stock is considered a top pickDollar Strength & High Return Trade Opportunity Guides - Newser
Biotech Momentum Builds In After-Hours Trading As BioAtla, Entero, And Sonnet Climb - Nasdaq
Can BioAtla Inc. stock rebound after recent weaknessMarket Rally & Low Risk Growth Stock Ideas - moha.gov.vn
BioAtla, Inc. (BCAB) -11.3% in Intraday Trading: What’s Driving the Move? - Stocks Telegraph
BioAtla Inc. (BCAB) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
The growth track for BioAtla Inc (BCAB) has changed recently - Setenews
[PRE 14A] BioAtla, Inc. Preliminary Proxy Statement - Stock Titan
BioAtla Reports Q3 2025 Financial Results and Progress - MSN
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Form 424B5 BioAtla, Inc. - StreetInsider
[424B5] BioAtla, Inc. Prospectus Supplement (Debt Securities) - Stock Titan
BioAtla Secures $7.5 Million Pre-Paid Advance - TipRanks
[8-K] BioAtla, Inc. Reports Material Event | BCAB SEC FilingForm 8-K - Stock Titan
BioAtla’s New Funding: A Double-Edged Sword for Shareholders - Ad-hoc-news.de
BioAtla Agrees to $22.5 Million in Financing Agreements - MarketScreener
BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing - Investing News Network
BioAtla, Inc. Secures $7.5 Million Financing to Support Operations During Strategic Partnership Negotiations - Quiver Quantitative
BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing - GlobeNewswire Inc.
Is BioAtla Inc (BCAB) Good For Your Portfolio? - fostersleader.com
Regression analysis insights on BioAtla Inc. performanceWeekly Trend Summary & AI Enhanced Market Trend Forecasts - newser.com
What catalysts could drive BioAtla Inc. stock higherProfit Target & Fast Gain Swing Trade Alerts - newser.com
Measuring BioAtla Inc.’s beta against major indicesTrade Analysis Report & Community Consensus Trade Alerts - newser.com
Ewing Sarcoma Market Research Report 2025-2035: Salarius, Eli Lilly, Pfizer, and BioAtla Lead by Driving Innovations in the Development of Novel Targeted Therapies - Yahoo Finance
BioAtla Inc. stock outlook for YEAR2025 Breakouts & Breakdowns & Safe Capital Allocation Plans - newser.com
Bioatla Shares Surge on Strong Clinical and Financial Results - Ad-hoc-news.de
Sentiment analysis tools applied to BioAtla Inc.Take Profit & Verified Momentum Watchlists - newser.com
What moving averages say about BioAtla Inc.Portfolio Return Summary & Accurate Entry/Exit Alerts - newser.com
BioAtla Inc (BCAB) can make a big difference with a little luck - Setenews
BioAtla outlines $800M peak sales target for Oz-V as FDA alignment paves way for phase III launch - MSN
Analyzing BioAtla Inc. with multi timeframe chartsMarket Sentiment Report & High Accuracy Swing Entry Alerts - newser.com
Analyzing BioAtla Inc. with risk reward ratio chartsTrade Performance Summary & Weekly Watchlist of Top Performers - newser.com
BioAtla, Inc.Common Stock (Nasdaq:BCAB) Stock Quote - Markets Financial Content
What to do if you’re stuck in BioAtla Inc.Sell Signal & Reliable Price Action Trade Plans - newser.com
Chart overlay techniques for tracking BioAtla Inc.July 2025 Sentiment & Technical Confirmation Alerts - newser.com
Is BioAtla Inc. a candidate for recovery playGap Down & AI Powered Trade Plan Recommendations - newser.com
BioAtla Tightens Belt But Analysts Remain Upbeat - Finimize
BioAtla, Inc. (NASDAQ:BCAB) Q3 2025 Earnings Call Transcript - Insider Monkey
Finanzdaten der Bioatla Inc-Aktie (BCAB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):